Immunologic basis and immunoprophylaxis of RhD induced hemolytic disease of the newborn [HDN]
IJI-Iranian Journal of Immunology. 2008; 5 (4): 189-200
in En
| IMEMR
| ID: emr-86766
Responsible library:
EMRO
ABSTRACT
RhD antigen is the most immunogenic and clinically significant antigen of red blood cells after ABO system. It has historically been associated with hemolytic disease of the newborn [HDN] which is now routinely prevented by the administration of polyclonal anti-D immunoglobulin. This management of HDN has proven to be one of the most successful cases of prophylactic treatment based on antibody mediated immune suppression [AMIS]. Despite the increasing efficiency of treatment, the mechanism of action of anti-D is not completely defined. There is a widespread interest in obtaining a reliable therapeutic monoclonal anti-D, due to difficulty of maintaining a pool of high titer volunteer donors for plasma collection and also increasing demand for antenatal prophylaxis and safety issues with plasma derived products. Candidate monoclonal anti-D preparations should demonstrate appropriate functionality in both in vitro and in vivo assays comparable to polyclonal anti-D immunoglobulin. These criteria are reviewed in addition to the factors regulating development of D specific immune response in D negative individuals and its suppression in HDN prophylaxis
Search on Google
Index:
IMEMR
Main subject:
Rh-Hr Blood-Group System
/
Blood Group Incompatibility
/
Immunization
/
Erythroblastosis, Fetal
/
Antibodies, Monoclonal
Limits:
Humans
Language:
En
Journal:
Iran. J. Immunol.
Year:
2008